LAUSR

Alzheimer's disease (AD) is the most prevalent disease associated with cognitive dysfunction. Current AD therapeutic agents have several gastrointestinal or psychological adverse effects and therefore, novel therapeutic agents with fewer adverse effects must be developed. Previously, we demonstrated that oleanolic acid, which is similar in chemical structure to maslinic acid, ameliorates cognitive impairment through the activation of tropomyosin receptor kinase (TrkB)–ERK–cAMP response element‐binding protein (CREB) phosphorylation and increased levels of brain‐derived neurotrophic factor (BDNF). In the present study, we investigate the effect of maslinic acid on cholinergic blockade‐induced memory impairment in mice.